Clinical characteristics and prognosis of castleman disease patients in a Chinese hospital: paraneoplastic pemphigus is an independent risk factor

Yibo Hua  
Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital

Chao Liang  
Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital

Jie Yang  
Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital

Luyang Wang  
Nanjing Medical University

Lei Xi  
Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital

Aimin Xu  
Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital

Shangqian Wang  ( wangshangqian@njmu.edu.cn )  
Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital

Zengjun Wang  
Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital

Research

Keywords: Castleman disease, paraneoplastic pemphigus, prognostic factors, survival

DOI: https://doi.org/10.21203/rs.3.rs-115006/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background Castleman disease (CD) is a rare lymphoproliferative disorder that has had limited clinical research. This study aims to detect the clinical manifestations, pathological features, and prognostic factors of this disease.

Methods This study retrospectively analyzed the information of 54 patients with CD hospitalized in a single centre. A Cox regression model was employed to perform univariate analysis and multivariate analysis in order to identify independent prognostic factors for survival.

Results Based on clinical classification, 26 patients (55.6%) had unicentric CD (UCD) and 28 patients (44.4%) had multicentric CD (MCD). Moreover, pathological classification identified 32 cases (59.3%) with hyaline vascular variant (HV), 3 (5.6%) with mixed cellular variant (Mix), and 19 (35.2%) with plasmacytic variant (PC). The MCD patients commonly exhibited clinical signs and symptoms, including fever, splenomegaly, and pleural effusion and/or ascites. Several clinical complications, such as liver injury, anemia, and polyradiculoneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, skin changes syndrome (POEMS) were more common in MCD patients. Univariate analysis showed that presence of paraneoplastic pemphigus (PNP) and elevated C-reactive protein (CRP) were unfavorable factors relating to CD patient survival. Multivariate analysis identified the presence of PNP as an independent prognostic factor in patients with CD.

Conclusions This study provided a panoramic elaboration of CD cases and showed the presence of PNP was an independent unfavorable factor.

Introduction

Castleman disease (CD) is a rare lymphoproliferative disorder that was first described by Dr. Benjamin Castleman 60 years ago[1, 2]. In recent decades, a number of case reports and reviews have presented the clinical manifestations[3–5], pathological features[6, 7], clinical treatment[8, 9], and have attempted to explain the pathogenesis[10, 11] of this complicated disease. However, due to the low morbidity, the study on CD has progressed slowly.

CD is a highly heterogeneous disorder that presents with diverse clinical manifestations. The unique clinical signs and complications associated with CD include paraneoplastic pemphigus (PNP), thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly, and polyradiculoneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, skin changes syndrome (POEMS)[12]. Clinically, CD is characterized as unicentric (UCD) and multicentric (MCD) based on the centricity. UCD is typically localized without systemic involvement, thus surgery is the main treatment. On the contrary, MCD is a systemic disorder that comprises two subgroups: human herpesvirus 8 (HHV8)-related MCD[13], and idiopathic multicentric Castleman disease (iMCD)[14, 15]. Systemic therapies are primarily applied to MCD. Based on pathology, CD can be classified into hyaline vascular variant (HV), plasmacytic variant
(PC) and mixed cellular variant (Mix). A systematic study on 416 CD patients established a novel classification system that provided a valuable model for the prediction of midterm outcome[16].

Although a large number of studies have focused on the clinical and pathological features during occurrence and progression of CD, few studies have examined the risk factors that influence CD prognosis. In this study, we reviewed a cohort of 54 patients with CD from a single center in China, in order describe the outcome of this disease with complex clinical manifestations, and define the prognostic factors.

**Methods**

**Patient characteristics**

We retrospectively collected the clinical and pathological data for 54 Chinese patients diagnosed with CD from 2008 to 2018 in The First Affiliated Hospital of Nanjing Medical University. The pathological data of each patient was based on the tissue specimens obtained from needle biopsy or surgical excision, and were reviewed by at least two experienced pathologists. The pathological classification of CD was established according to Flendrig and Kellers criteria[17, 18]. The clinical classification of all enrolled cases was based on physical and imageological examination. Other definitions in this study included: (1) anemia, defined as hemoglobin < 110 g/l for females and < 120 g/l for males; (2) hypoalbuminemia, defined as serum albumin < 35 g/l; (3) elevated lactate dehydrogenase (LDH), defined as serum LDH > 270 U/L; (4) elevated C-reactive protein (CRP), defined as serum CRP > 8 mg/L; (5) elevation of Anti-Streptolysin O (ASO), defined as serum ASO > 200 IU/ml; and (6) elevation of erythrocyte sedimentation rate (ESR), defined as ESR > 20 mm/h for females and > 15 mm/h for males.

**Follow-up**

Enrolled patients were followed until January 2020. Data were collected through telephone, letters, and case records. Survival time was defined as the period from diagnosis to death or last interview. None of the enrolled patients were lost to follow-up.

**Statistical analysis**

Data were analyzed with SPSS 26.0 software for windows (SPSS, Inc., Chicago, IL, USA). The $\chi^2$-test was used to analyze the relationship between pathological/clinical subtypes and clinical features. The Kaplan-Meier method was applied to analyze the survival curve. The Log-Rank test was used to compare the differences in the survival curve. A Cox regression model was employed to perform univariate analysis and multivariate analysis in order to identify independent prognostic factors for survival. A P-value < 0.05 was considered to be statistically significant.

**Results**

**Patient characteristics**
All 54 patients diagnosed with CD were hospitalized between February 2008 and August 2018. Within this cohort, 23 patients were aged from 12 to 40 years old, and 31 patients were between 41 and 82 years old (median, 43 years). A total of 24 patients were male and 30 were female. Based on the clinical subtype, 26 patients had UCD and 28 had MCD. According to the histopathological characteristics of all 54 specimens, 32 cases were HV, 19 cases were PC, and only 3 cases were Mix (Table 1).
Table 1  
Characteristics of the 54 Castleman disease patients.

| Age                      |          |
|--------------------------|----------|
| Mean ± SD(year)          | 42.9 ± 14.4 |
| ≤ 40                     | 23       |
| > 40                     | 31       |

| Gender                   |          |
|--------------------------|----------|
| Male                     | 24       |
| Female                   | 30       |

| Clinical subtype         |          |
|--------------------------|----------|
| UCD                      | 30       |
| MCD                      | 24       |

| Pathological subtype     |          |
|--------------------------|----------|
| HV                       | 32       |
| MIX                      | 3        |
| PC                       | 19       |

| Main complaints           |          |
|--------------------------|----------|
| Tumor mass or lymph node enlargement | 31       |
| Fever, hypodynamia or myalgia | 12       |
| Skin/mucosal ulcers, blisters or stomatitis | 9        |
| Others                    | 10       |

| Therapy                   |          |
|---------------------------|----------|
| Biopsy only               | 2        |
| Surgery                   | 23       |
| Surgery + CHOP chemotherapy | 9        |
| CHOP-like chemotherapy    | 9        |
| Rituximab + CHOP chemotherapy | 6        |

SD, standard deviation; UCD, unicentric Castleman disease; MCD, multicentric Castleman disease; HV, hyaline-vascular variant; Mix, mixed cellular variant; PC, plasmacytic variant; IVIG, intravenous immunoglobulin; CHOP, cyclophosphamide, vincristine and prednisone.
The 54 patients were categorized into four groups according to the main complaints; each patient may have had one or more complaints. The first group included 31 patients with enlarged superficial lymph nodes or serendipitous tumor masses, which were confirmed to be CD after biopsies or surgeries. The second group included 12 patients with recurring symptoms, such as fever, hypodynamia, or myalgia. After physical examination, ultrasonography, or CT, enlarged lymph nodes or tumor masses were found and then confirmed to be CD after biopsies or surgeries. The third group included 9 patients with skin ulcers, blisters, or stomatitis, which were considered to be PNP and were diagnosed as CD after biopsies or surgeries. The remaining 10 cases complained of non-typical symptoms, such as abdominal distension, pain, or body edema (Table 1).

**Clinical Symptoms And Complications**

At the time of hospitalization, several obvious signs and symptoms occurred in CD patients, including fever, splenomegaly, and pleural effusion and/or ascites. Fever was observed in 11 patients and splenomegaly was observed in 12 patients. Pleural effusion and/or ascites were determined in 16 patients by CT scans (Table 2).

| Age                          |   |   |
|------------------------------|---|---|
| IVIG + glucocorticoids       | 11| 20.4% |
| Symptomatic treatment        | 2 | 3.7%  |
| Tocilizumab + CHOP chemotherapy | 1 | 1.9%  |

SD, standard deviation; UCD, unicentric Castleman disease; MCD, multicentric Castleman disease; HV, hyaline-vascular variant; Mix, mixed cellular variant; PC, plasmacytic variant; IVIG, intravenous immunoglobulin; CHOP, cyclophosphamide, vincristine and prednisone.
Table 2  
Distribution of Clinical characteristics according to clinical and pathological subtypes.

|                      | Total | Clinical subtype | Pathological subtype |      |      |      |      |      |      |      |
|----------------------|-------|------------------|----------------------|------|------|------|------|------|------|------|
|                      |       | UCD (n = 30)     | MCD (n = 24)         | PC  | Mix | HV  |      |      |      |      |
| Signs and symptoms   |       |                  |                      |      |      |      |      |      |      |      |
| Fever                | 11    | 2                | 9                    | 0.007|      |      | 7    | 1    | 3    | 0.028|
| Splenomegaly         | 12    | 3                | 9                    | 0.011|      |      | 5    | 0    | 7    | 0.743|
| Pleural effusion and/or ascites | 16 | 5               | 11                   | 0.020|      |      | 8    | 0    | 8    | 0.203|
| Clinical complications|       |                  |                      |      |      |      |      |      |      |      |
| Pulmonary infection  | 16    | 9                | 7                    | 0.947|      |      | 6    | 0    | 10   | 0.980|
| Kidney injury        | 18    | 8                | 10                   | 0.245|      |      | 8    | 0    | 10   | 0.433|
| Liver injury         | 9     | 3                | 6                    | 0.165|      |      | 4    | 1    | 4    | 0.450|
| Anemia               | 19    | 8                | 11                   | 0.143|      |      | 8    | 1    | 10   | 0.433|
| AIHA                 | 3     | 2                | 1                    | 1.000|      |      | 3    | 0    | 0    |      |
| PNP                  | 9     | 4                | 5                    | 0.489|      |      | 5    | 1    | 3    | 0.131|
| POEMS syndrome       | 6     | 0                | 6                    | 0.005|      |      | 3    | 0    | 3    | 0.659|
| Other abnormal laboratory data |       |                  |                      |      |      |      |      |      |      |      |
| Lower serum albumin | 17    | 8                | 9                    | 0.394|      |      | 10   | 1    | 6    | 0.012|
| Elevated LDH         | 6     | 1                | 5                    | 0.078|      |      | 4    | 1    | 1    | 0.058|
| Elevated CRP         | 10    | 1                | 9                    | 0.003|      |      | 6    | 1    | 3    | 0.062|
| Elevated ESR         | 13    | 2                | 11                   | 0.001|      |      | 6    | 1    | 6    | 0.325|
| Elevated ASO         | 8     | 3                | 5                    | 0.443|      |      | 7    | 0    | 1    | 0.003|

UCD, unicentric Castleman disease; MCD, multicentric Castleman disease; HV, hyaline-vascular variant; Mix, mixed cellular variant; PC, plasmacytic variant; PNP, paraneoplastic pemphigus; AIHA, autoimmune haemolytic anaemia; POEMS syndrome, polyneuropathy, organomegaly, endocrinopathy, monoclonal gammapathy and skin changes; LDH, lactate dehydrogenase; CRP, C-reaction protein; ESR, erythrocyte sedimentation rate; ASO, Anti-Streptolysin O

Bold: P < 0.05. P values were two-tailed and based on the Pearson chi-square test
Pulmonary infection was diagnosed in 16 patients whose main complaints were fever and cough, and X-ray film or CT assisted with the definite diagnosis. A total of 18 cases were diagnosed with kidney injury, based on proteinuria and significantly elevated serum creatinine. Liver injury was observed in 9 patients with abnormal elevation of serum alanine aminotransferase (ALT) and glutamic oxalacetic transaminase (AST). In total, 18 patients were diagnosed with anemia, according to obviously decreased hemoglobin, and 3 patients were diagnosed with autoimmune hemolytic anemia (AIHA) by positive Coombs’ test results. Nine patients with skin involvement were diagnosed with PNP, with chief complaints of skin or mucosal ulcers, blisters, or pigmentation. Six MCD cases were diagnosed with POEMS syndrome, with presence of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (Table 2).

Patients with MCD may exhibit more symptoms and complications

In this retrospective study, 30 (55.6%) patients were diagnosed with UCD and 24 (44.4%) patients were diagnosed with MCD (Table 1). MCD patients commonly exhibited clinical signs and symptoms, including in 9 of the 11 patients with fever (P < 0.01), 9 of the 12 patients with splenomegaly (P < 0.05), and 11 of the 16 patients with pleural effusion and/or ascites (P < 0.05) (Table 2).

In all CD patients with clinical complications, liver injury, anemia, and POEMS syndrome were more likely to be found in MCD patients. Of the 9 patients with liver injury, 6 had MCD, and of the 19 patients with anemia, 11 had MCD; however, these differences were not statistically significant (P = 0.165 and P = 0.143, respectively). All 6 patients with POEMS syndrome were diagnosed with MCD (P < 0.01). There were no significant differences in the remaining clinical complications between patients with UCD and MCD. Furthermore, the MCD subtype was found in 7 of the 16 patients with pulmonary infection, in 10 of the 18 patients with kidney injury, in 1 of the 3 patients with AIHA, and in 5 of the 9 patients with PNP (Table 2).

Relationship between pathological subtypes and clinical symptoms and complications

Of the total included patients, 32 (59.3%) cases were HV, 19 (35.2%) cases were PC, and only 3 (5.6%) cases were Mix (Table 1). Since the sample size of the Mix cases was too small for statistical analysis, only PC and HV cases were used for analysis. In terms of the signs and symptoms, fever was more likely to occur in patients with PC than in patients with HV (P < 0.05). With regards to clinical complications, all 3 patients with AIHA were diagnosed with PC (P < 0.05), and of the 9 patients with PNP, 5 patients were classified as PC and 3 were classified as HV; however, this difference was not statistically significant (P = 0.131) (Table 2).

Patients with MCD may show abnormal laboratory parameters

Of the 54 included patients, 17 showed a pretreatment albumin level of < 35 g/l. Patients with PC were more likely to have lower serum albumin than those with HV (P < 0.05). Prior to treatment, 6 patients showed elevated lactate dehydrogenase (LDH) levels, which tended to be more common in patients with
MCD or PC, although no significant difference was found (P = 0.078, P = 0.058). Prior to treatment, patients with MCD also showed elevated CRP and ESR levels; of the 10 patients with elevated CRP, 9 were diagnosed with MCD (P < 0.01), and of the 13 patients with elevated ESR, 11 were diagnosed with MCD (P < 0.01). Eight patients had an ASO level > 200 IU/ml, and patients with PC were more likely to have elevated ASO (P < 0.01) (Table 2).

**Treatment**

Two patients who complained of enlarged superficial lymph nodes only received lymph node biopsy, and both refused further treatment. A total of 23 patients without serious complications received surgery, and then took a “watch and wait” strategy. Nine patients were treated with the CHOP regimen (cyclophosphamide 600 mg/m², vincristine 1 mg/m², and prednisone 1 mg/kg) after surgery, and 8 were classified as UCD. In MCD cases, 9 received CHOP, 6 received R-CHOP (at least two doses of rituximab 375 mg/m²), and 1 received tocilizumab. Patients with PNP received standard treatment with intravenous infusion of immunoglobulin (IVIG) and glucocorticoid (prednisone, methylprednisolone, or dexamethasone) after surgical removal of the tumor mass. Two patients in critical condition received supportive treatment only, including anti-infection, blood pressure control, and hemodialysis, which led to symptomatic improvement (Table 1).

**Univariate analysis identified PNP and elevated CRP as unfavorable risk factors**

Among the 54 evaluated cases, the longest follow-up duration was 143 months, and the median follow-up duration was 57.5 months. Univariate analysis of prognostic factors using the Cox univariate analysis identified two risk factors: Presence of PNP (HR = 31.895, P < 0.01) and elevated CRP (HR = 5.363, P < 0.05) (Table 3). Kaplan-Meier analysis and log-rank test also indicated a significantly shorter survival for patients with PNP (P < 0.001) or elevated CRP (P = 0.021) (Fig. 1). In addition, univariate analysis showed that fever, pleural effusion and/or ascites, and low serum albumin level may be unfavorable risk factors, but these results were not statistically significant (0.05 < P < 0.1) (Table 3).
Table 3
Univariate and multivariate analyses of the 54 patients with Castleman disease.

| Clinical characteristics | N  | Univariate analysis | Multivariate analysis |
|--------------------------|----|---------------------|-----------------------|
|                          |    | P      | HR   | 95% CI HR | P    | HR   | 95% CI HR |
| Gender                   |    |         |      |           |      |       |           |
| Male                     | 24 | 0.164  | 0.312| 0.060–1.609|
| Female                   | 30 |         |      |           |      |       |           |
| Age                      |    |         |      |           |      |       |           |
| ≤40                      | 23 | 0.197  | 0.018| 0.000–8.118|
| >40                      | 31 |         |      |           |      |       |           |
| Clinical subtype         |    |         |      |           |      |       |           |
| UCD                      | 30 | 0.984  | 1.016| 0.226–4.562|
| MCD                      | 24 |         |      |           |      |       |           |
| Pathological subtype     |    |         |      |           |      |       |           |
| HV                       | 32 | 0.252  | 0.409| 0.089–1.887|
| PC + Mix                 | 22 |         |      |           |      |       |           |
| Fever                    | 11 | 0.078  | 3.898| 0.859–17.697|
| Splenomegaly             | 12 | 0.686  | 1.404| 0.271–7.258|
| Pleural effusion and/or ascites | 16 | 0.087  | 3.735| 0.826–16.882|
| Pulmonary infection      | 16 | 0.256  | 2.529| 0.510–12.534|

UCD, unicentric Castleman disease; MCD, multicentric Castleman disease; HV, hyaline-vascular variant; Mix, mixed cellular variant; PC, plasmacytic variant; PNP, paraneoplastic pemphigus; AIHA, autoimmune haemolytic anaemia; POEMS syndrome, polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes; LDH, lactate dehydrogenase; CRP, C-reaction protein; ESR, erythrocyte sedimentation rate; ASO, Anti-Streptolysin O; HR, hazard ratio; 95% CI, 95% confidence interval.

Bold: P < 0.05. P values were based on Cox proportional-hazards model

Factors with P < 0.15 in univariate analysis went into the Cox multivariate analysis
### Clinical characteristics

| Clinical characteristics | N  | Univariate analysis |         | Multivariate analysis |         |
|--------------------------|----|---------------------|---------|-----------------------|---------|
|                          |    | P       | HR   | 95% CI    | P       | HR   | 95% CI    |
| Kidney injury            | 18 | 0.499   | 1.678| 0.374–7.524 |         |       |         |
| Liver injury             | 9  | 0.954   | 0.939| 0.112–7.850 |         |       |         |
| Anemia                   | 19 | 0.721   | 0.741| 0.143–3.840  |         |       |         |
| AIHA                     | 3  | 0.686   | 0.045|           |         |       |         |
| PNP                      | 9  | 0.002   | 31.895| 3.711–274.135| 0.007   | 22.834| 2.309–225.817 |
| POEMS                    | 6  | 0.630   | 1.696| 0.198–14.527 |         |       |         |
| Presence of complications| 37 | 0.249   | 3.534| 0.413–30.232 |         |       |         |
| Lower serum albumin      | 17 | 0.060   | 5.135| 0.936–28.169 | 0.468   | 3.086 | 0.147–64.580 |
| Elevated LDH             | 6  | 0.674   | 1.585| 0.185–13.570 |         |       |         |
| Elevated CRP             | 10 | 0.040   | 5.363| 1.080–26.638 | 0.639   | 3.190 | 0.025–407.041 |
| Elevated ESR             | 13 | 0.566   | 0.538| 0.065–4.482  |         |       |         |
| Elevated ASO             | 8  | 0.217   | 2.820| 0.544–14.613 |         |       |         |

UCD, unicentric Castleman disease; MCD, multicentric Castleman disease; HV, hyaline-vascular variant; Mix, mixed cellular variant; PC, plasmacytic variant; PNP, paraneoplastic pemphigus; AIHA, autoimmune haemolytic anaemia; POEMS syndrome, polyneuropathy, organomegaly, endocrinopathy, monoclonal gammapathy and skin changes; LDH, lactate dehydrogenase; CRP, C-reactionprotein; ESR, erythrocyte sedimentation rate; ASO, Anti-Streptolysin O; HR, hazard ratio; 95% CI, 95% confidence interval.

**Bold:** P < 0.05. P values were based on Cox proportional-hazards model

Factors with P < 0.15 in univariate analysis went into the Cox multivariate analysis

---

**Multivariate Analysis Identified PNP As The Only Risk Factor**

A Cox proportional hazards model was used for multivariate analysis, in which characteristics with P-values < 0.15 in univariate analysis and those with clinical significance, were included. These
characteristics included fever, pleural effusion and/or ascites, PNP, low serum albumin, and elevated CRP. Multivariate analysis showed that the presence of PNP was an independent risk factor associated with the prognosis of CD (HR = 22.834, P < 0.01). Although elevated CRP was identified as an unfavorable risk factor in univariate analysis, its P-value was 0.639 in multivariate analysis (Table 3).

Discussion

Compared to other malignant hemopathy, such as leukemia and lymphoma, research on CD is limited due to its rarity. Although CD is not a malignant disease, it has been associated with an increased risk of diverse complications. Although studies have focused on establishing the diagnostic criteria of CD[16, 19], additional cohort studies are required to better understand its prognosis factors.

Our study retrospectively analyzed 54 patients with CD in a single center from 2008 to 2018. We found that MCD may present with more systemic manifestations such as fever, splenomegaly, and pleural effusion and/or ascites. Furthermore, POEMS syndrome, as a complication, also occurred more frequently in patients with MCD. MCD commonly presented with serological abnormalities corresponding to inflammatory markers, including elevated CRP and ESR levels. These results indicated that MCD may induce systemic inflammation; thus, systemic therapies were primarily applied to MCD. In terms of pathology, PC cases were more likely to have fever, and decreased albumin and elevated ASO were often detected in the serum of PC patients.

Univariate analysis identified the presence of PNP and elevated CRP in serum as risk factors influencing the survival of CD patients. However, when all candidate risk factors, including fever, pleural effusion and/or ascites, PNP, low serum albumin, and elevated CRP were included in multivariate analysis, the presence of PNP was the only independent unfavorable risk factor for the prognosis of CD. This result was consistent with the research of Dr. Dong[4].

PNP is a rare mucocutaneous autoimmune disease associated with neoplasm that was first described in 1990[20]. The clinical features of PNP include stomatitis, mucositis, and skin lesions. Furthermore, PNP is frequently associated with hematologic neoplasms, including non-Hodgkin lymphoma, chronic lymphocytic leukemia, and CD[21, 22]. In this series of CD cases, 9 were considered to have PNP. Clinical classification showed that 4 were UCD and 5 were MCD, while pathological classification showed that 5 were PC, 1 was Mix, and 3 were HV. Although several previous studies have reported that PNP usually occurs in UCD or HV[4, 20], our study found no correlation between PNP and clinical or pathological subtype. The main complaints of these patients were polymorphic skin lesions, including skin blisters, ulcers, and lichenoid eruptions, while stomatitis and mucositis were also observed. Some studies revealed that patients with PNP tended to die from severe infection due to immunosuppressive therapy, associated malignancy, and bronchiolitis obliterans[23, 24]. Thus, with poor prognosis and high mortality, the treatment of PNP is challenging. After complete tumor resection, patients with PNP should receive systemic corticosteroids combined with other immunosuppressive agents, including cyclosporine, cyclophosphamide, azathioprine, and mycophenolate mofetil[25]. In our retrospective study, all 9 CD
patients with PNP received IVIG and steroids after tumor mass removal, but 5 died by the date of the last follow-up.

The centricity and pathology type are important clinical factors that could help to predict prognosis and guide treatment at early diagnosis. Several recent studies have reported that MCD patients have significantly worse survival rates than UCD patients[26, 27]. Furthermore, based on pathological classification, PC patients were also reported to have a worse prognosis than both HV and Mix patients[16]. Unfortunately univariate analysis in our study could not identify centricity (UCD or MCD) and histopathology types (HV or PC) as prognostic factors in this series of patients. It will be important to collect more cases of CD for further analysis in order to investigate the correlations between the centricity/pathology type and the prognosis.

Complete resection of the tumor mass was reported to be the standard treatment for UCD[28]. In our study, 29 of the 31 UCD patients received primary surgical resection, 1 case was too sick to tolerate surgery and only received symptomatic and supportive treatment, and the remaining case refused surgery after biopsy diagnosis. For MCD, the optimal treatment for has not been well established. The MCD patients in our study received a variety of agents, including corticosteroids, cytotoxic chemotherapy, immunoglobulin, rituximab, and anti-IL-6 (tocilizumab). MCD patients could benefit from cytotoxic chemotherapy based on that used in lymphoma therapy[29]. In our study, most of MCD the patients received cytotoxic chemotherapy as a first line therapy. Rituximab, a monoclonal anti-CD20 antibody, was used in HIV- and/or HHV8- positive MCD patients[30, 31]. Tocilizumab, a humanized anti-IL-6 monoclonal antibody was approved for treatment of CD in Japan in 2005[32], and has been shown to induce remission in MCD patients in a series of case reports[33, 34]. These target therapy regimens have the potential to be alternative treatments for CD after replacement of chemotherapy. Due to the high heterogeneity of CD, precision and individual therapy should be urgently applied in the clinic.

The present study had some limitations. First, it was a retrospective study and there might be a bias for patient selection and data collection. Second, the sample size requires to be expanded for further analysis.

**Conclusions**

CD was an unusual lymphoproliferative disorder that continues to present clinical challenges. Our study helped to identify the clinical characteristics and prognosis of CD patients. The results indicated that the presence of PNP was an independent risk factor, and should be paid more attention during diagnosis and treatment.

**Abbreviations**

CD: Castleman disease; UCD: Unicentric castleman disease; MCD: Multicentric castleman disease; iMCD: Idiopathic multicentric Castleman disease; HV: hyaline vascular variant; PC: Plasmacytic variant; POEMS:
polyradiculoneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, skin changes syndrome; PNP: Paraneoplastic pemphigus; CRP: C-reactive protein; HHV8: Human herpesvirus 8; LDH: lactate dehydrogenase; ASO: Anti-Streptolysin O; ESR: erythrocyte sedimentation rate; ALT: Alanine aminotransferase; AST: Glutamic oxalacetic transaminase; AIHA: Autoimmune hemolytic anemia; IVIG: Intravenous infusion of immunoglobulin.

**Declarations**

**Authors’ contributions**

Conception and design: SQW, ZJW. Acquisition of data: YBH, CL, JY, LYW, AMX. Pathological diagnosis: LX. Analysis and interpretation of data: YBH, CL, JY. Drafting the manuscript: YBH, SQW. All authors approved the final version. YBH, CL and JY contributed equally to this work.

**Funding**

The study was supported by National Natural Science Foundation of China (81800587). Clinical follow up and data analysis were supported by this funding.

**Availability of data and materials**

All methods were carried out in accordance with relevant guidelines and regulations. The data and materials are available.

**Ethics Declarations**

**Ethics approval and consent to participate**

Written Informed consent was obtained from all the adult patients and parents or guardians for participants under 18 years old. Dead patients’ kin or legally authorized representative provided written informed consent. This study was approved by ethical committee of The First Affiliated Hospital of Nanjing Medical University.

**Consent for publication**

Written informed consent for publication was obtained from all participants.

**Competing Interests**

The authors declare no conflict of interests in association with the present study.

**References**
[1] CASE records of the Massachusetts General Hospital Weekly Clinicopathological Exercises: Case 40011. N Engl J Med, 1954. 250(1): p. 26-30.

[2] CASTLEMAN, B., L. IVerson and V.P. MENENDEZ, Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer, 1956. 9(4): p. 822-30.

[3] Herrada, J., et al., The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med, 1998. 128(8): p. 657-62.

[4] Dong, Y., et al., Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor. Br J Haematol, 2015. 169(6): p. 834-42.

[5] Abramson, J.S., Diagnosis and Management of Castleman Disease. J Natl Compr Canc Netw, 2019. 17(11.5): p. 1417-1419.

[6] Keller, A.R., L. Hochholzer and B. Castleman, Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer, 1972. 29(3): p. 670-83.

[7] Cronin, D.M. and R.A. Warnke, Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol, 2009. 16(4): p. 236-46.

[8] Newman, S.K., et al., Taking Control of Castleman Disease: Leveraging Precision Medicine Technologies to Accelerate Rare Disease Research. Yale J Biol Med, 2015. 88(4): p. 383-8.

[9] van Rhee, F., et al., International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood, 2018. 132(20): p. 2115-2124.

[10] Hengge, U.R., et al., Update on Kaposi’s sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis, 2002. 2(6): p. 344-52.

[11] Hengge, U.R., et al., Update on Kaposi’s sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis, 2002. 2(6): p. 344-52.

[12] Szalat, R. and N.C. Munshi, Diagnosis of Castleman Disease. Hematol Oncol Clin North Am, 2018. 32(1): p. 53-64.

[13] Dossier, A., et al., Human herpesvirus 8-related Castleman disease in the absence of HIV infection. Clin Infect Dis, 2013. 56(6): p. 833-42.

[14] Liu, A.Y., et al., Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematol, 2016. 3(4): p. e163-75.
[15]. Yu, L., et al., Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood, 2017. 129(12): p. 1658-1668.

[16]. Talat, N. and K.M. Schulte, Castleman's disease: systematic analysis of 416 patients from the literature. Oncologist, 2011. 16(9): p. 1316-24.

[17]. Keller, A.R., L. Hochholzer and B. Castleman, Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer, 1972. 29(3): p. 670-83.

[18]. Cronin, D.M. and R.A. Warnke, Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol, 2009. 16(4): p. 236-46.

[19]. Fajgenbaum, D.C., et al., International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood, 2017. 129(12): p. 1646-1657.

[20]. Anhalt, G.J., et al., Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med, 1990. 323(25): p. 1729-35.

[21]. Kaplan, I., et al., Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncol, 2004. 40(6): p. 553-62.

[22]. Lehman, V.T., et al., Diagnostic imaging in paraneoplastic autoimmune multiorgan syndrome: retrospective single site study and literature review of 225 patients. Int J Dermatol, 2015. 54(4): p. 424-37.

[23]. Leger, S., et al., Prognostic factors of paraneoplastic pemphigus. Arch Dermatol, 2012. 148(10): p. 1165-72.

[24]. Anhalt, G.J., Paraneoplastic pemphigus. J Investig Dermatol Symp Proc, 2004. 9(1): p. 29-33.

[25]. Frew, J.W. and D.F. Murrell, Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome). Dermatol Clin, 2011. 29(4): p. 607-12.

[26]. Shin, D.Y., et al., Clinical dissection of multicentric Castleman disease. Leuk Lymphoma, 2011. 52(8): p. 1517-22.

[27]. Zhang, X., et al., Clinical characteristics and outcomes of Castleman disease: A multicenter study of 185 Chinese patients. Cancer Sci, 2018. 109(1): p. 199-206.

[28]. Talat, N., A.P. Belgaumkar and K.M. Schulte, Surgery in Castleman's disease: a systematic review of 404 published cases. Ann Surg, 2012. 255(4): p. 677-84.

[29]. Lee, J.H., et al., Multicentric Castleman disease complicated by tumor lysis syndrome after systemic chemotherapy. Leuk Res, 2010. 34(1): p. e42-5.
[30]. Gerard, L., et al., Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman’s disease: ANRS 117 CastlemaB Trial. J Clin Oncol, 2007. 25(22): p. 3350-6.

[31]. Bower, M., et al., Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med, 2007. 147(12): p. 836-9.

[32]. Nishimoto, N., et al., Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood, 2005. 106(8): p. 2627-32.

[33]. Turcotte, L.M., et al., Sustained remission of severe Multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance. Pediatr Blood Cancer, 2014. 61(4): p. 737-9.

[34]. Cai, S., et al., Treatment of multicentric Castleman disease through combination of tocilizumab, lenalidomide and glucocorticoids: Case report. Medicine (Baltimore), 2019. 98(46): p. e17681.